ORPHA:251858
Medulloblastoma with extensive nodularity
Also known as: MBEN
Publications
568
79.7th percentile
Trials
1
Interventional, condition-specific
Researchers
1,156
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Medulloblastoma with extensive nodularity (MBEN) is a histological variant of medulloblastoma, an embryonic malignancy, most often located in the inferior medullary velum and then growing into the fourth ventricle, and presenting in infants and young children with symptoms of increased intracranial pressure such as headache, listlessness, vomiting, diplopia and papilledema. It is often associated with Gorlin syndrome and has a relatively good prognosis.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016710
- UMLS:C1334970
- NCIT:C5407
Additional Mondo synonyms (4)
cerebellar neuroblastoma · medulloblastoma with extensive nodularity · medulloblastoma with extensive nodularity and advanced neuronal differentiation · nodular medulloblastoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
568 matched papers (365 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
568
568 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
568 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
365 in the last 10 years · medium confidence · 79.7th percentile (publications denominator)
Phrase hits: 568 · MeSH hits: 0
Who's working on it?
1,156
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Rutkowski S12 papers · 2025
Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 02Pietsch T11 papers · 2023
Institute of Neuropathology, Brain Tumor Reference Center of the German Society for Neuropathology and Neuroanatomy, University of Bonn, German Center for Neurodegenerative Diseases, Bonn, Germany.
Papers in Europe PMC - 03Mynarek M10 papers · 2025
Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 04Korshunov A9 papers · 2024
Clinical Cooperation Unit Neuropathology, German Cancer Research Center; and Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Papers in Europe PMC - 05Clifford SC8 papers · 2025
Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
Papers in Europe PMC - 06Gajjar A8 papers · 2025
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.
Papers in Europe PMC - 07Pfister SM8 papers · 2024
Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.
Papers in Europe PMC - 08Lafay-Cousin L7 papers · 2025
Division of Pediatric Hematology Oncology and Bone Marrow Transplantation, Alberta Children's Hospital, Calgary, Alberta, Canada.
Papers in Europe PMC - 09Okonechnikov K7 papers · 2025
Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Papers in Europe PMC - 10Pajtler KW7 papers · 2025
Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting. 203 trials are registered for medulloblastoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).
medium confidence · 80.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: medulloblastoma
203
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07087002·RECRUITING·GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Not reviewed·Conditions: Medulloblastoma · Central Nervous System Embryonal Tumor · Refractory Medulloblastoma · Recurrent Medulloblastoma·Matched via name phrase
- NCT07715357·NOT YET RECRUITING·Evaluation of The Radioprotective Effect of 3D-Printed Intraoral Stents in Children With Brain Cancer.
Not reviewed·Conditions: Medulloblastoma Tumor·Matched via name phrase
- NCT06161519·RECRUITING·PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Not reviewed·Conditions: Glioma · Medulloblastoma · Ependymoma · Glioblastoma·Matched via name phrase
- NCT06898684·RECRUITING·Medulloblastoma Online Video-based Exercise Pilot Study
Not reviewed·Conditions: Medulloblastoma, Childhood·Matched via name phrase
- NCT05106296·RECRUITING·Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Not reviewed·Conditions: Ependymoma · Medulloblastoma · Glioblastoma · Primary Brain Tumor·Matched via name phrase
- NCT01356290·RECRUITING·Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Not reviewed·Conditions: Medulloblastoma Recurrent · Ependymoma Recurrent · ATRT Recurrent · Rare CNS Tumor Recurrent·Matched via name phrase
- NCT06607692·RECRUITING·Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Not reviewed·Conditions: Solid Tumor Cancer · Medulloblastoma · High Risk Neuroblastoma · High Grade Gliomas·Matched via name phrase
- NCT07516353·NOT YET RECRUITING·my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Not reviewed·Conditions: Sarcoma · Osteosarcoma · Ewing Sarcoma · Rhabdomyosarcoma·Matched via name phrase
- NCT04541082·RECRUITING·Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Not reviewed·Conditions: Central Nervous System Neoplasms · Glioblastoma · Gliosarcoma, Adult · Anaplastic Oligodendroglioma·Matched via name phrase
- NCT06396481·NOT YET RECRUITING·Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Not reviewed·Conditions: GBM · DIPG Brain Tumor · Medulloblastoma·Matched via name phrase
- NCT07584499·RECRUITING·Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) · Nasopharyngeal Carcinoma · Lymphoepithelial Carcinoma · Rhabdomyosarcoma·Matched via name phrase
- NCT05382338·RECRUITING·A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Not reviewed·Conditions: Childhood Medulloblastoma·Matched via name phrase
- NCT07017816·RECRUITING·A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
Not reviewed·Conditions: CNS Malignancies · Medulloblastoma Recurrent · ATRT Recurrent · Pineoblastoma·Matched via name phrase
- NCT06193759·RECRUITING·Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Not reviewed·Conditions: Medulloblastoma, Childhood · Atypical Teratoid/Rhabdoid Tumor of CNS · Embryonal Tumor With Multilayered Rosettes · Pineoblastoma·Matched via name phrase
- NCT07698899·RECRUITING·A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
Not reviewed·Conditions: Recurrent Medulloblastoma · Refractory Medulloblastoma · CNS Metastases · Central Nervous System Metastasis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Medulloblastoma with extensive nodularity — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Medulloblastoma with extensive nodularity" OR "cerebellar neuroblastoma" OR "medulloblastoma with extensive nodularity and advanced neuronal differentiation" OR "nodular medulloblastoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Medulloblastoma with extensive nodularity" OR "cerebellar neuroblastoma" OR "medulloblastoma with extensive nodularity and advanced neuronal differentiation" OR "nodular medulloblastoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"medulloblastoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MBEN
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T10:52:52.944Z
